PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.77%
Revenue growth of 7.77% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
11.04%
Gross profit growth of 11.04% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
39.63%
EBIT growth of 39.63% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
44.97%
Operating income growth of 44.97% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
44.92%
Net income growth of 44.92% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
44.95%
EPS growth of 44.95% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
44.95%
Diluted EPS growth of 44.95% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
0.00%
Share change of 0.00% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if the modest difference matters long-term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.52%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.77%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
59.52%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 17.89%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
59.52%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.39%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.21%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 57.21% over a decade. Joel Greenblatt might see a standout compounder of earnings.
119.21%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 41.12%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
119.21%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 30.59%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.94%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.12%
Asset growth of 2.12% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
6.96%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
-54.14%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.